The FDA expects to miss its March 1 deadline for approving Zogenix's (ZGNX +13.2%) application...


The FDA expects to miss its March 1 deadline for approving Zogenix's (ZGNX +13.2%) application for its Zohydro painkiller. The FDA didn't provide a reason for the delay, which may last several weeks, but nor did it indicate that there are any problems with Zogenix's filing. In December, FDA advisors said Zohydro should only get approval once Zogenix has taken measures to help limit opioid abuse. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs